Research Analysts Issue Forecasts for Catalyst Pharmaceuticals, Inc.’s FY2020 Earnings (CPRX)
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – SunTrust Banks dropped their FY2020 earnings per share estimates for shares of Catalyst Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash now forecasts that the biopharmaceutical company will earn $0.01 per share for the year, down from their previous estimate of $0.05. SunTrust Banks has a “Buy” rating and a $5.00 price target on the stock. SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ FY2021 earnings at $0.51 EPS.
TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/research-analysts-issue-forecasts-for-catalyst-pharmaceuticals-inc-s-fy2020-earnings-cprx/1705524.html.
A number of other equities analysts also recently commented on the company. Zacks Investment Research downgraded Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st. Finally, Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. Catalyst Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $5.50.
Catalyst Pharmaceuticals (CPRX) traded up $0.03 during trading hours on Monday, reaching $2.96. The company had a trading volume of 1,003,700 shares, compared to its average volume of 874,875. Catalyst Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $3.24.
A number of large investors have recently made changes to their positions in CPRX. Bank of New York Mellon Corp raised its holdings in Catalyst Pharmaceuticals by 3.6% during the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock worth $135,000 after purchasing an additional 2,404 shares in the last quarter. JPMorgan Chase & Co. bought a new stake in Catalyst Pharmaceuticals during the first quarter worth approximately $155,000. Vanguard Group Inc. raised its holdings in Catalyst Pharmaceuticals by 0.5% during the first quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock worth $5,865,000 after purchasing an additional 15,600 shares in the last quarter. Geode Capital Management LLC raised its holdings in Catalyst Pharmaceuticals by 0.3% during the first quarter. Geode Capital Management LLC now owns 462,677 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 1,446 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Catalyst Pharmaceuticals during the first quarter worth approximately $746,000. 40.19% of the stock is currently owned by hedge funds and other institutional investors.
In other Catalyst Pharmaceuticals news, insider Patrick J. Mcenany acquired 20,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was acquired at an average cost of $2.58 per share, for a total transaction of $51,600.00. Following the completion of the transaction, the insider now owns 4,471,026 shares in the company, valued at approximately $11,535,247.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.79% of the company’s stock.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.